[
    [
        {
            "time": "",
            "original_text": "[买入评级]恒瑞医药(600276)：SHR-1701和SHR1209获批临床 新药研发管线深化",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "SHR-1701",
                    "SHR1209",
                    "获批临床",
                    "新药研发"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[买入评级]恒瑞医药(600276)：SHR-1701和SHR1209获批临床 新药研发管线深化",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "485亿资金争夺20股：主力资金重点出击17股(名单)",
            "features": {
                "keywords": [
                    "资金争夺",
                    "主力资金",
                    "股票名单"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "485亿资金争夺20股：主力资金重点出击17股(名单)",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级]医药国家药品监督管理局发布《接受药品境外临床试验数据的技术指导原则》点评：接受境外实验数据细则公布 新药上市“时差”有望显著缩短",
            "features": {
                "keywords": [
                    "国家药品监督管理局",
                    "境外临床试验",
                    "技术指导原则",
                    "新药上市",
                    "时差缩短"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[推荐评级]医药国家药品监督管理局发布《接受药品境外临床试验数据的技术指导原则》点评：接受境外实验数据细则公布 新药上市“时差”有望显著缩短",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药：两款注射剂获批 将开展I期临床试验",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "注射剂",
                    "获批",
                    "I期临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药：两款注射剂获批 将开展I期临床试验",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "天士力：生物药平台价值初显 引领天士力价值重估",
            "features": {
                "keywords": [
                    "天士力",
                    "生物药平台",
                    "价值重估"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天士力：生物药平台价值初显 引领天士力价值重估",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]